Elexacaftor/Tezacaftor/Ivacaftor Increases Vitamin A and D in Cystic Fibrosis
Researchers assessed the effect of elexacaftor/tezacaftor/ivacaftor (ETI) on vitamin A, D, E, and K levels in people with cystic fibrosis.
Diagnosis & Disease Information
ATS Guideline: Outpatient Management of Pediatric Post-Prematurity Respiratory Disease
How should clinicians handle the outpatient management of infants, children, and adolescents with post-prematurity respiratory disease? A summary of updated recommendations from the American Thoracic Society offers guidance.
Assessing the Risk of SARS-CoV-2 Infection in Patients With Cystic Fibrosis
While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.
- Loading...
Loading...
Next post in News
Loading... 
Loading...